TY - JOUR

T1 - Established and emerging biological activity markers of inflammatory bowel disease

AU - Nielsen, O H

AU - Vainer, B

AU - Madsen, S M

AU - Seidelin, J B

AU - Heegaard, N H

PY - 2000/2

Y1 - 2000/2

N2 - Assessment of disease activity in inflammatory bowel disease (IBD), i.e., ulcerative colitis (UC) and Crohn's disease (CD), is done using clinical parameters and various biological disease markers. Ideally, a disease marker must: be able to identify individuals at risk of a given disorder, be disease specific, mirror the disease activity and, finally, be easily applicable for routine clinical purposes. However, no such disease markers have yet been identified for IBD. In this article, classical disease markers including erythrocyte sedimentation rate, acute phase proteins (especially orosomucoid and CRP), leukocyte and platelet counts, albumin, neopterin, and beta2-microglobulin will be reviewed together with emerging disease markers such as antibodies of the ANCA/ASCA type, cytokines (e.g., IL-1, IL-2Ralpha, IL-6, IL-8, TNF-alpha, and TNF-alpha receptors) and with various adhesion molecules. It is concluded that none of the pertinent laboratory surrogate markers of disease activity in IBD are specific or sensitive enough to replace basic clinical observation such as the number of daily bowel movements, general well-being, and other parameters in parallel. Further studies are highly warranted to identify and assess the clinical importance and applicability of new laboratory markers for the diagnosis or the disease activity of IBD.

AB - Assessment of disease activity in inflammatory bowel disease (IBD), i.e., ulcerative colitis (UC) and Crohn's disease (CD), is done using clinical parameters and various biological disease markers. Ideally, a disease marker must: be able to identify individuals at risk of a given disorder, be disease specific, mirror the disease activity and, finally, be easily applicable for routine clinical purposes. However, no such disease markers have yet been identified for IBD. In this article, classical disease markers including erythrocyte sedimentation rate, acute phase proteins (especially orosomucoid and CRP), leukocyte and platelet counts, albumin, neopterin, and beta2-microglobulin will be reviewed together with emerging disease markers such as antibodies of the ANCA/ASCA type, cytokines (e.g., IL-1, IL-2Ralpha, IL-6, IL-8, TNF-alpha, and TNF-alpha receptors) and with various adhesion molecules. It is concluded that none of the pertinent laboratory surrogate markers of disease activity in IBD are specific or sensitive enough to replace basic clinical observation such as the number of daily bowel movements, general well-being, and other parameters in parallel. Further studies are highly warranted to identify and assess the clinical importance and applicability of new laboratory markers for the diagnosis or the disease activity of IBD.

KW - Acute-Phase Proteins

KW - Antibodies

KW - Antibodies, Antineutrophil Cytoplasmic

KW - Biomarkers

KW - Blood Sedimentation

KW - Cell Adhesion Molecules

KW - Humans

KW - Inflammatory Bowel Diseases

KW - Interleukins

KW - Leukocyte Count

KW - Mannans

KW - Neopterin

KW - Phosphopeptides

KW - Platelet Count

KW - Risk Factors

KW - Serum Albumin

KW - Tumor Necrosis Factor-alpha

KW - beta 2-Microglobulin

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1111/j.1572-0241.2000.t01-1-01790.x

DO - 10.1111/j.1572-0241.2000.t01-1-01790.x

M3 - Journal article

C2 - 10685736

VL - 95

SP - 359

EP - 367

JO - The American Journal of Gastroenterology

JF - The American Journal of Gastroenterology

SN - 0002-9270

IS - 2

ER -